drugset
drugset / Trial / NCT01584505

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD

NCT01584505 ↗

Phase 2 Completed 191 enrolled Chiesi Farmaceutici S.p.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Cardiac Safety Study

Timeline

Start
2012-04
Primary completion
2012-09
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CHF1535 Unknown — Inhaled
Subject CHF5992 Unknown — —

Indications

chronic obstructive pulmonary disease